|
Dr. Vaporciyan was born in Detroit, Michigan. He attended the Honors College at the University of Michigan from 1982 to 1985 where he received a Bachelor of Science Degree in Cellular and Molecular Biology. He received his MD degree from the University of Michigan Medical School in 1989 and began his General Surgery residency at the University of Texas Health Science Center in Houston, Texas. In the midst of this residency he took two years to also complete a postdoctoral fellowship in the Department of Pathology at the University of Michigan Medical School. His general surgery training was completed in 1996 upon which he began his cardiothoracic training at the combined UT MD Anderson/Texas Heart Institute residency. Upon completion in 1998 he joined the faculty at UT MD Anderson Cancer Center in the Department of Thoracic and Cardiovascular Surgery as an Assistant Surgeon and Assistant Professor of Surgery. Dr. Vaporciyan is a Diplomate of the American Board of Surgery and of the American Board of Thoracic Surgery. He is also a member of the Society of Thoracic Surgeons, the American Thoracic Society and a member of the Texas Medical Association. Information Ara
Vaporciyan, M.D. Offices: Department of Thoracic
and Cardiovascular Surgery Education:
Hospital Training:
Board Certifications:
Clinical Interests: Dr. Vaporciyan's clinic interests include thoracic malignancies, specifically lung and esophageal cancer as well as mesothelioma, cardiac tumors, tumors metestatic to the lung and primary chest wall and mediastinal tumors. Dr. Vaporciyan also provides vascular surgery services for extremity and abdominal operations performed at M. D. Anderson. Research Interests: Dr. Vaporciyan's research interests are centered on acute pulmonary injury. Standard treatment of lung cancer (ie surgery, radiotherapy and chemotherapy) is associated with some degree of acute lung injury, sometimes severe enough to result in added morbidity and mortality. A number of studies are underway to identify the mechanisms involved in lung injury which will set the stage for molecular and genetic manipulations to limit these processes. In addition, novel treatments of lung cancer are being developed by other members of this department and will simultaneously be evaluated for their effects on normal lung. Methods to limit collateral damage to the normal lung will be developed in conjunction with these novel treatment approaches. Finally, clinical trials will be conducted to assess the effectiveness of new methods of limiting pulmonary injury in our patients currently being treated for lung cancer.
|